PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1375956-7	1992	In vivo activated effectors when incubated with anti-asialo-GM1 antibody plus complement lost completely their ability to lyse YAC-1 targets.	G(M1) Ganglioside	60-63	ADP-ribosyltransferase 1	Mus musculus	127-132	
3206532-6	1988	Antibody and complement depletion experiments showed that both anti-YAC-1 and anti-P815 activity could be depleted with antiserum to the asialo-GM1 cell surface marker, but was unaffected by anti-Lyt-1.2 and anti-Lyt-2.2 treatment.	G(M1) Ganglioside	144-147	ADP-ribosyltransferase 1	Mus musculus	68-73	
9826367-7	1998	The cells were confirmed to be NK cells by abrogation of YAC-1 cell cytotoxicity by treatment in vitro and in vivo with anti-asialo-GM1.	G(M1) Ganglioside	132-135	ADP-ribosyltransferase 1	Mus musculus	57-62	
3899934-5	1985	Moreover, the anti-YAC-1 lytic activity was partially sensitive to anti-Thy1.2 serum and was completely abrogated by treatment of peritoneal nonadherent cells with monoclonal anti-asialo GM1 antibodies.	G(M1) Ganglioside	187-190	ADP-ribosyltransferase 1	Mus musculus	19-24	
7240748-3	1981	Intravenous injection of anti-asialo GM1, which has been shown to eliminate natural killer (NK) activity in vitro in the presence of complement, completely abolished NK activity against lymphoma cell line (YAC-1) in spleen cells from athymic nude mice as well as from conventional mice.	G(M1) Ganglioside	37-40	ADP-ribosyltransferase 1	Mus musculus	206-211